SEATTLE, Oct. 31, 2017 /PRNewswire/ -- LumiThera Inc., a clinical stage private medical device company creating a non-invasivephotobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has completed the Series B round of financing. The company raised $5.5M to support further development of its LT-300 device for the
"We are pleased with the investor interest in the company and have oversubscribed the Series B round," stated Clark Tedford, Ph.D., President and CEO. "This is an exciting time for the company and the infusion of new capital will allow us to execute on our multi-center clinical trials and initial OUS commercialization activities."
"LumiThera has made significant strides in developing a novel treatment for a debilitating eye disease," says Arthur Taylor, LumiThera, Board of Directors. "Patients currently have limited options and vision loss is a growing global unmet medical need and the focus of our PBM platform technology."
LumiThera offered up to $5M of preferred shares in the Series B round. WaterStone Capital, a China-and Seattle-based group was the lead investor and Seattle-based RPR Venture co-invested in the B round. WaterStone Capital's founding partner, Yigang Yang will be joining the LumiThera Board of Directors. "WaterStone is very excited to be part of the LumiThera team and looks forward to helping in the global commercialization of the PBM technology for ocular disease," stated Yigang Yang.
The company is currently conducting a prospective, randomized, double masked, clinical trial in 30 dry AMD subjects called the LIGHTSITE I study with the LumiThera LT-300 light delivery system.
Visit the Company's website at www.lumithera.com.
About LumiThera Inc.LumiThera is a clinical-stage medical device company focused on the use of photobiomodulation ("PBM"), using non-invasive light emitting diodes ("LED") to treat patients with acute and chronic ocular diseases and disorders. The Company is currently developing an ophthalmologist LED office-based instrument to be used in treating dry Age-related Macular Degeneration.
2017 LumiThera Inc., All rights reserved.
View original content:http://www.prnewswire.com/news-releases/lumithera-closes-series-b-round-of-financing-300546083.html
SOURCE LumiThera Inc.
Subscribe to our Free Newsletters!
Opportunistic infections are microbial infections that can cause disease in persons with a weak ...
The state health insurance programs provide health care support to the below poverty line (BPL) ...
There is a lining between the lungs and chest wall known as Pleura. The dismissal of pleura by a ...View All